Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages 1345-1349

  Hussein, Ayad Ahmed ^a   Al Zaben, Abdulhadi ^a   Ghatasheh, Lubna ^a   Natsheh, Abeer ^a   Hammada, Tuka ^a   Abdel Rahman, Fawzi ^a   Abu Jazar, Husam ^a   Sharma, Shanta ^a   Najjar, Rula ^a   Frangoul, Haydar ^b  

^a KING HUSSEIN CANCER CENTER   (Jordan)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

Author keywords

Hematopoietic stem cell transplantation; Risk stratification; Thalassemia major

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS C; HUMAN; INFANT; JORDAN; LYMPH NODE IRRADIATION; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BETA-THALASSEMIA; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84879223224     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24493     Document Type: Article

References (16)

1. Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: Past, present and future. Bone Marrow Transplant 2008;41:109-117.
2. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322:417-421.
3. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011;118:3479-3488.
4. Weatherall DJ. Thalassemia as a global health problem: Recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010;1202:17-23.
5. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: A grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003;9:512-518.
6. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-1146.
8. Gharaibeh HF, Gharaibeh MK. Factors influencing health-related quality of life of thalassaemic Jordanian children. Child Care Health Dev 2012;38:211-218.
9. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998;850:270-275.
10. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-The role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005;36:839-845.
11. McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011;46:27-33.
12. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996;87:2082-2088.
13. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood 2011;117:1745-1750.
14. Hongeng S, Chuansumrit A, Hathirat P, et al. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli). Bone Marrow Transplant 2002;30:409-410.
15. Resnick IB, Aker M, Tsirigotis P, et al. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Bone Marrow Transplant 2007;40:957-964.
16. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. Hepatology 1999;29:1893-1899.